Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa

✍ Scribed by Mitchell, James E. ;Tareen, Basir ;Sheehan, William ;Agras, Stewart ;Brewerton, Timothy D. ;Crow, Scott ;Devlin, Michael ;Eckert, Elke ;Halmi, Katherine ;Herzog, David ;Marcus, Marsha ;Powers, Pauline ;Stunkard, Albert ;Walsh, B. Timothy

• Publisher: Wiley (John Wiley & Sons)
• Year: 2000
• Tongue: English
• Weight: 143 KB
• Volume: 28
• Category: Article
• ISSN: 0276-3478
• DOI: 10.1002/(sici)1098-108x(200007)28:1<1::aid-eat1>3.0.co;2-h

✦ Synopsis

Objective:

This paper addresses the lack of a standard protocol for pharmacotherapy trials for patients with bulimia nervosa (bn) and anorexia nervosa (an).

Method:

Twenty-two surveys were sent to established researchers in the field of eating disorders to elicit their opinions regarding medication trials, including baseline laboratory tests, the optimal length/frequency of medication management sessions, and the information that should or should not be included in these sessions.

Results:

Sixteen of 22 researchers completed and returned the survey. their answers are the basis of the data presented.

Discussion:

We propose a battery of screening laboratory tests for both conditions. we suggest 30-45-min initial medication management sessions in both an and bn trials with 15-min follow-ups to be held weekly for an subjects, and weekly for 2 weeks, then biweekly for 2 weeks, then monthly, for bn subjects. we also recommend that published trials should include explicit details of medication management.